AND-017 is under clinical development by Kind Pharmaceuticals and currently in Phase II for Beta Thalassaemia. According to GlobalData, Phase II drugs for Beta Thalassaemia have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AND-017’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AND-017 overview
AND-017 is under development for the treatment of anemia in non-dialysis-dependent chronic kidney disease patients, beta-thalassemia and cancer related anemia (Anemia) receiving chemotherapy and non receiving chemotherapy, myelodysplastic syndromes (MDS) anemia, sickle cell disease (SCD). The drug candidate is administered by oral route as capsule.
Kind Pharmaceuticals overview
Kind Pharmaceuticals (Kind Pharma) focuses on research and development of new drugs. Kind Pharma is headquartered in Hangzhou, Zhejiang, China.
For a complete picture of AND-017’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
